Project Grant R44AA031925
Award Date 9/15/25
Completion Date 2/28/26
Dollars Obligated $320K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This federal Project Grant award of $139,851 was made by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research on the therapeutic potential of the psychedelic compound psilocybin in treating opioid use disorder (OUD) and post-traumatic stress disorder (PTSD), which are highly comorbid conditions. The project aims to investigate the neurobiological mechanisms by which...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $914,324 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Demerx, Inc. in Miami, FL. The grant supports the investigational new drug development of noribogaine for the treatment of alcohol use disorder (AUD). Key details include: Demerx, Inc. is a clinical-stage drug development company advancing noribogaine, a novel "psychoplastogen" therapeutic agent, for the treatment of AUD. The grant will...
- This $246,000 federal Project Grant awarded on June 15, 2025 by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research at Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to explore psilocybin's effects on behavioral states, motivated task acquisition, and the associated cellular and brain-wide substrates, from dendritic spines to large-scale...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $901,666 Project Grant to Research Triangle Institute (RTI International) to develop small molecule modulators of the RXFP3 receptor as potential therapeutic agents for alcohol use disorder (AUD). The project aims to further optimize and evaluate the effectiveness of the RXFP3 negative allosteric modulators (NAMs) RLX-33 and RLX-79 in animal models of alcohol...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $399,076 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center in Memphis, TN. The purpose of this grant is to develop a rapid and reliable platform for evaluating and repurposing FDA-approved drugs to target chronic alcohol tolerance and dependence associated with Alcohol Use Disorder (AUD). The project will leverage the nematode Caenorhabditis elegans as an...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the neural mechanisms by which the psychedelic compound psilocybin acts on the frontal cortex of the mouse brain. The $149,804 award will fund research at Cornell University to use advanced calcium imaging techniques to elucidate how psilocybin influences the activity of specific inhibitory interneuron populations and pyramidal neuron...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...